Alterity Therapeutics Ltd ATH

Morningstar Rating
A$0.19 −0.01 (5.13%)
View Full Chart

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ATH is trading at a LOCK|tT@^G premium.
Price
A$0.19
Fair Value
LOCK|H$G?B&w
Uncertainty
LOCK|%# $<T>@
1-Star Price
LOCK|K#x>%vl
5-Star Price
LOCK|HP^NCK
Economic Moat
LOCK|@ymn&
Capital Allocation
—

News

Trading Information

Previous Close Price
A$0.20
Day Range
A$0.18–0.20
52-Week Range
A$0.18–0.79
Bid/Ask
A$0.19 / A$0.21
Shares Outstanding
229.10M
Market Cap
A$42.38M
Volume/Avg
687,705 / 365,996

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
—
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Dividend Payment Schedule
—
Total Yield
—

Company Profile

Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson's disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment: research and development into Parkinsonian and other neurodegenerative disorders.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
11

Valuation

Metric
ATH
Price/Earnings (Normalized)
—
Price/Book Value
1.09
Price/Sales
—
Price/Cash Flow
—
Price/Earnings
No chart available

Financial Strength

Metric
ATH
Quick Ratio
14.26
Current Ratio
14.52
Interest Coverage
—
Quick Ratio
ATH

Profitability

Metric
ATH
Return on Assets (Normalized)
—
Return on Equity (Normalized)
—
Return on Invested Capital (Normalized)
—
Return on Assets
ATH

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
LOCK|f!<?@@LOCK|yKzH$131B
Regeneron Pharmaceuticals Inc
REGN
LOCK|&^^!$%LOCK|CvNV$95B
Moderna Inc
MRNA
LOCK|!@G^<gLOCK|>@v$79B
argenx SE ADR
ARGX
LOCK|>>m>LzNLOCK|tRN$59B
BeOne Medicines Ltd ADR
ONC
LOCK|j@%qDj%LOCK|^%$45B
Royalty Pharma PLC Class A
RPRX
LOCK|FrqN?S#>LOCK|S%@?&$30B
Incyte Corp
INCY
LOCK|#p^PT&?LOCK|@#$23B
BioNTech SE ADR
BNTX
LOCK|l?@RzRLOCK|w%$20B
Alnylam Pharmaceuticals Inc
ALNY
LOCK|VlN$fYLOCK|$Ynx$19B
BridgeBio Pharma Inc
BBIO
LOCK|l!gs$>@LOCK|zT$15B

Sponsor Center